tbuckley/cabot-search huggingface dataset:
ACTR-52. CLINICAL AND RADIOLOGICAL LONG TERM OUTCOME OF ACOUSTIC NEUROMAS (KOOS GRADE I – IV) AFTER STEREOTACTIC RADIOSURGERY
Authors: Daniel Ruess, Lea Poehlmann, Harald Treuer, Martin Kocher, Maximilian I. Ruge
Journal: Neuro-Oncology (2016)

In the management of acoustic neuroma (AN) stereotactic radiosurgery (SRS) has evolved as widely accepted treatment option for small-sized tumors (Koos I and II). For larger AN (Koos III and IV) microsurgery is treatment of choice. However, for patients not suitable for microsurgery SRS might be an alternative that balances tumor control, hearing preservation. In this single center retrospective analysis (1991 - 2015) we included all patients with previously untreated AN who underwent single session LINAC or Cyberknife® based SRS. Patient data were analyzed and correlated (Pearson`s coefficient) with the different Koos grades in terms of tumor control, preservation of hearing, course of median pure tone averages (PTA) and adverse events rated by Common Terminology Criteria for Adverse Events (CTCAE; v4.03). 301 patients (f:m=151:150, median age 59 years ±13.6, range 17–84) were identified with a mean follow-up of 50.9 months (range 3–265). Mean tumor volume was 1.85 ml ±2.4 (range 0.1–23.7). With regard to the Koos classification 52 patients were considered as grade I, 162 as grade II, 42 and 45 as grade III and IV, respectively. At last follow-up after SRS 94% of the patients showed radiological tumor control. There was no significant correlation (p < 0.113) between Koos grades I/II vs III/IV and radiological tumor control. Median PTA of Koos I/II tumors increased from 37,2 dB prior to SRS up to 55,6 dB at last follow-up and in case of Koos III/IV tumors from 46,2 dB up to 68,2 dB. The rate of transient facial nerve dysfunction and transient trigeminal nerve impairment each with CTCAE grade 1/2 occurred with a higher rate in Koos III/IV tumors. SRS for AN shows reliable long term tumor control and a high rate of hearing preservation and without considerable permanent side effects. Therefore, SRS can be proposed as safe and effective treatment option for AN, even with higher Koos grades.
Factors Influencing Disease Expression in Hemochromatosis
Authors: D. H.G. Crawford
Journal: Annual Review of Nutrition (1996)

Genetic hemochromatosis is one of the most common inherited disorders in Caucasian populations. The disease frequency in Caucasian populations in Australia, Europe, and the United States is 1:300-400. The basic genetic defect remains unknown, although the hemochromatosis gene is closely linked to histocompatibility antigen (HLA) A, thus allowing early diagnosis in members of affected families. Many factors—environmental, genetic, and nongenetic in nature—influence the degree of iron loading in affected individuals. In particular, pathologic and physiologic blood loss and blood donation influence iron stores in hemochromatosis. The iron concentration in the liver is an important determinant of survival because a hepatic iron concentration in excess of 400 pmol/g dry weight is usually associated with cirrhosis. Patients with cirrhosis secondary to hemochromatosis are at risk of heptocellular carcinoma and complications of portal hypertension. The combination of improved awareness of the condition and the use of HLA typing to identify affected family members has led to earlier diagnosis and therapy, and to an improvement in overall survival
Endoscopy
Authors: Edward B. Benedict
Journal: New England Journal of Medicine (1955)

THE word endoscope comes from the Greek ενδον (within) combined with σκοπειν (to examine) and means an instrument for the examination of the interior of a hollow viscus. Although at first thought endoscopy might seem to cover a very narrow area, it is not so in fact, for the endoscopist sees many of the most interesting cases in the hospital, and his field of endeavor covers much important literature.BronchoscopyTechnicWetrich1 has demonstrated an apparatus to protect the physician during the application of topical anesthesia in the tuberculous patient. It consists of a face shield to which an ordinary . . .
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Authors: Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Monica M. Colvin, Mark H. Drazner, Gerasimos S. Filippatos, Gregg C. Fonarow, Michael M. Givertz, Steven M. Hollenberg, JoAnn Lindenfeld, Frederick A. Masoudi, Patrick E. McBride, Pamela N. Peterson, Lynne Warner Stevenson, Cheryl Westlake
Journal: Circulation (2017)
Ischemic but Not Pharmacological Preconditioning Requires Protein Synthesis
Authors: Nanritsu Matsuyama, John E. Leavens, David McKinnon, Glenn R. Gaudette, Tunc O. Aksehirli, Irvin B. Krukenkamp
Journal: Circulation (2000)

Background —Ischemic preconditioning (IPC) and pharmacological preconditioning (PPC) have both been shown to confer cardioprotective effects. However, the role of protein synthesis in preconditioning is unclear. Methods and Results —Isolated rabbit hearts were treated with cycloheximide (CHx, 10 μmol/L), a protein synthesis inhibitor at the translational level, before 2 cycles of IPC (5 minutes of global ischemia/5 minutes of reperfusion, n=6) or PPC by pinacidil (PIN, 10 μmol/L; n=6), an ATP-sensitive potassium channel opener. Six rabbit hearts received actinomycin D (Act D, 20 μmol/L; n=6), a protein synthesis inhibitor at the transcriptional level, before IPC. The left anterior descending coronary artery was then occluded for 60 minutes and reperfused for 120 minutes. Control hearts received no treatment before prolonged ischemia (n=6). Left ventricular pressure, action potential duration, and coronary flow were measured. Infarct size is expressed as a percentage of the area at risk. IPC (n=6) and PIN (n=8) hearts experienced reduced infarct size compared with control hearts (22±3% and 27±2% versus 46±3%, IPC and PIN versus control; P &lt;0.01). Translational blockade (CHx) reversed the IPC infarct size reduction effect (22±3% versus 48±4%, IPC versus CHx+IPC; P &lt;0.01) but not the effects of pinacidil (27±2% versus 29±3%, PIN versus CHx+PIN; P =NS). Transcriptional blockade (Act D) did not abolish the IPC effect (23±5% versus 22±3%, Act D+IPC versus IPC; P =NS). There were no significant differences in electromechanical function consequent to CHx and Act D treatment. Conclusions —These findings suggest an important role for protein synthesis in the mechanism for IPC-mediated protection at the translational level, which may be different from PPC.
Ooze Blues
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL COLLEGES OF THE UNITED STATES
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer
Authors: D. Rischin, B. Burmeister, P. Mitchell, M. Boyer, M. Macmanus, E. Walpole, M. Feigen, M. M. Tin, D. Ball
Journal: Journal of Clinical Oncology (2004)

7077 Background: Gefitinib ('Iressa', ZD1839) enhances tumor radioresponsiveness in preclinical studies, and is approved as monotherapy in non-small-cell lung cancer (NSCLC). The aim was to establish the recommended doses of gefitinib, carboplatin, and paclitaxel given concurrently with radical radiation therapy (RT) in patients (pts) with stage III NSCLC. Methods: Pts with histologic diagnosis of NSCLC, stage III disease (no pleural effusion or cervical lymphadenopathy), ECOG PS 0/1, weight loss ≤10%, and no prior RT for NSCLC were eligible. Pts received RT (60 Gy/30 fx/6 weeks) to the primary site and involved regional nodes. Concurrent oral gefitinib 250 mg/day and carboplatin AUC 2, weekly were administered with RT on dose level 1, and weekly paclitaxel was added at 25, 35, and 45 mg/m2 at dose levels 2, 3, and 4, respectively. The first 6 pts continued gefitinib after chemoRT; however, the protocol was amended to cease gefitinib at the end of chemoRT, following reports of interstitial lung disease elsewhere. Results: A total of 15 pts have been enrolled in this study from 4 institutions: median age (range), 65 (50–76) years; M/F, 11/4; stage IIIA/IIIB, 9/6; squamous-cell/large-cell/adenocarcinoma, 8/5/2. Dose escalation up to dose level 4 has been completed without any dose limiting toxicities, and additional pts are currently being treated on an expanded cohort to confirm the safety of this dose level and to obtain further efficacy data. Treatment was well tolerated: esophagitis (grade 2, n=2; grade 3, n=2); pneumonitis (grade 2, n=5; 4 of which occurred in pts who continued gefitinib after chemoRT); diarrhea (grade 2, n=1; grade 3, n=1). The PET complete response (CR) rate in 11 evaluable pts was 55%. The CT CR rate was 27% and partial response rate was 64%, for an overall response rate of 91%. Conclusions: This regimen of concurrent gefitinib, radical RT (60 Gy) and full dose weekly carboplatin and paclitaxel was generally well tolerated. Preliminary efficacy data are encouraging and updated survival and toxicity data will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca AstraZeneca
The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients
Authors: R. P. Eaton
Journal: JAMA (1985)

Improvement in range of motion and in strength of digital flexion and extension is reported in three diabetic subjects with the syndrome of limited joint mobility. Therapy was accomplished with sorbinil, an inhibitor of the enzyme aldose reductase, which inhibits the polyol pathway. We propose that reduction in collagen hydration secondary to reduced tissue content of polyols may participate in the clinical response. (<i>JAMA</i>1985;253:1437-1440)
Mortality pattern in high risk patients after acute myocardial infarction in the thrombolytic era: A combined analysis of contemporary survival studies Yee Guan Yap, Trinh Duong, Martin Bland, Marek Malik, Christian Torp-Pederson, Lars Kober, Stuart Connolly, Robin Roberts, Bradley Marchant, A. John Camm. St. George's Hospital Medical School, London, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
Reply
Authors: J L Ravdin
Journal: Gut (1995)

of cytokines such as transforming growth factor ,B is likely to be an epiphenonemon of the inflammatory process.Finally, we support the view of Cavallini et al that while calcification might contribute to the pathogenesis of chronic pancreatitis in its later stages, there is no well documented evidence fulfilling Koch's postulates that it is probably a significant aetiological factor in the disease.Hence, we also cannot support the hypothesis of the Marseilles school.2We consider that the disease known as 'chronic pancreatitis' is not a single pathological entity but rather a group of different aetiologies and pathogenetic processes sharing a few common morphological end points.3Within this overall group, we anticipate that a predisposition based upon an identifiable genetic abnormality is the likely primary aetiological factor responsible for at least a proportion of cases of chronic pancreatitis.Whether this defect occurs within the pathway of alcohol metabolism or is responsible for promoting an inappropriate cell mediated cytotoxic response to some pancreatic cellular antigen is presently unknown.Nevertheless, answers to such questions are vital if biologically appropriate treatment regimens for different aetiologically and pathogenetically distinct types of 'chronic pancreatitis' are to be developed and affected patients treated more rationally than at present.
Science and the "Human life bill"
Authors: H. S. Meyer
Journal: JAMA (1981)

RECENTLY, the Subcommittee on Separation of Powers of the Senate Judiciary Committee heard testimony on S 158, the "human life bill." The hearings raise interesting questions about the role of science in the resolution of moral issues and about scientific consensus. <h3>Background</h3> In a 1973 decision, the Supreme Court of the United States in<i>Roe vs Wade</i>upheld the right of a woman to obtain an abortion until the stage of fetal "viability" without the interference of the state.<sup>1,2</sup>An amendment to the Constitution could reverse this decision, and, in fact, one has been proposed. Meanwhile, however, a bill has also been proposed to Congress by which its sponsors would attempt to reverse the 1973 Supreme Court decision. The bill (S 158) states: Congress finds that present day scientific evidence indicates a significant likelihood that actual human life exists from conception. The Congress further finds that the fourteenth amendment
A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastases
Authors: A. M. P. Omuro, J. J. Raizer, L. E. Abrey
Journal: Journal of Clinical Oncology (2004)

1567 Background: The prognosis of recurrent brain metastasis (BM) is poor. We designed a Phase I trial combining temozolomide (TMZ), an agent with efficacy in BM, with vinorelbine, a lipophilic agent with activity against a variety of solid tumors, to establish the maximum tolerated dose (MTD) of vinorelbine for this combination. Methods: Patients with solid tumors and recurrent or progressive BM were eligible. Chemotherapy consisted of 28 day cycles with TMZ (150 mg/m2 on days 1 to 7 and 15 to 21) and vinorelbine (days 1 and 8 at escalating doses). The starting dose was 15 mg/m2, with increments of 5 mg/m2 for each cohort of 3 patients, until MTD was reached. Results: 14 pts enrolled (5 men); median age was 59 (41–76) years; median KPS was 80 (70–100). Seven pts had non-small cell lung CA, 3 small-cell lung cancer, 3 breast and 1 renal cell. Vinorelbine dose/m2 was 15mg in 7, 20mg in 4 and 25mg in 3. Six patients were taken off study for disease progression, 3 for toxicity, 3 for withdrawal of consent, 1 for clinical deterioration and 1 for non-compliance. The median time to progression was 3 (1–7) months. Of the 10 that completed at least one cycle, 1 achieved a minor response, 3 stable disease and 6 progressed (5 in the brain, 1 systemically). Median overall survival was 7.5 (2–13) months. Grades 3/ 4 neutropenia in 4 patients and thrombocytopenia in 5 were the only serious adverse events. Conclusions: To date this regimen has been well tolerated and a phase II study is warranted to define efficacy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough Integrated Therapeutics (Schering-Plough)
THE COEXISTENCE OF HODGKIN'S DISEASE AND AMEBIASIS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Die Trübungsformen der menschlichen Linse
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ASSOCIATION NEWS.
Authors: G. H. Rohe
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viruses Could Trigger Cancer, But Might Not Be a Primary Cause
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preventing School Violence: No Easy Answers
Authors: L. Lamberg
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal